Venture capital player Medicxi, a spinout of Index Ventures, has launched a $300m late-stage life sciences fund, Medicxi Growth 1 (MG1).
Latest funding round with Target Partners brings the company's total funding to $27m
GP to buy the Spanish electro-medicine manufacturer Indiba from Minerva for around €60m
Rubicon provided fresh capital to support the acquisition of the automotive fluids business
No management changes are planned, and the firm will be run by the executive team